Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.53 |
| ▸ | FGFR1 | P11362 | 3/20 | 0.53 |
| ▸ | KDR | P35968 | 2/20 | 0.53 |
| ▸ | PORCN | Q9H237 | 2/20 | 0.48 |
| ▸ | ABCB1 | P08183 | 5/20 | 0.45 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.44 |
| ▸ | HTR2A | P28223 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
| ▸ | HTR2B | P41595 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.43 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | AKR1C2 | P52895 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7079643 | 0.81 | POLB (0.60) | EGFRFGFR1KDRPORCNALDH1A1 | |
| SCHEMBL7082536 | 0.79 | PORCN (0.53) | EGFRFGFR1KDRPORCNABCB1 | |
| SCHEMBL7078347 | 0.78 | PORCN (0.60) | EGFRFGFR1KDRPORCNALDH1A1 | |
| SCHEMBL7084050 | 0.77 | POLB (0.53) | KDRPORCNALDH1A1HTTHTR2A | |
| SCHEMBL7078069 | 0.76 | PORCN (0.53) | PORCNALDH1A1GAAHTR2AHTR2C | |
| SCHEMBL1568942 | 0.76 | PORCN (0.60) | PORCNALDH1A1SMN1; SMN2ROCK2EPHX1 | |
| SCHEMBL7077998 | 0.74 | PORCN (0.53) | EGFRFGFR1KDRPORCNALDH1A1 | |
| SCHEMBL7079139 | 0.74 | PORCN (0.53) | PORCNALDH1A1HTR2AHTR2CHTR2B | |
| SCHEMBL16907385 | 0.74 | KDR (0.65) | EGFRFGFR1KDRPORCNHTR2A | |
| SCHEMBL29739402 | 0.74 | ALDH1A1 (0.53) | PORCNPTGS2ALDH1A1GAAHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6638953-B2 | Central nervous system disorders; anxiety | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-28 | — | — | US | disclosed |
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | SMITHKLINE BEECHAM P.L.C. | 2003-06-05 | — | — | US | disclosed |
| US-6235758-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-22 | — | — | US | disclosed |
| EP-0808312-B1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 2000-11-02 | — | — | EP | disclosed |
| US-5990133-A | TREATING CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS ANXIETY OR DEPRESSION | SMITHKLINE BEECHAM P.L.C. (GB) | 1999-11-23 | — | — | US | disclosed |
| EP-0808312-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1997-11-26 | — | — | EP | disclosed |
| WO-1996023783-A1 | INDOLE DERIVATIVES AS 5-HT RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM PLC (GB) | 1996-08-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030105139-A1 | Indole derivatives as 5-HT receptor antagonist | HTR5A, HTR2C, HTR1A | EGFR 603/4885FGFR1 4051/4885KDR 1780/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.